Published in Law and Health Weekly, January 19th, 2008
Ronald W. Barrett, Ph.D., chief executive officer of XenoPort, stated, "We are pleased to report these advancements in our XP19986 and XP21279 clinical development programs. Given our earlier positive results with single doses of XP19986 in GERD patients, we believe this new GERD clinical trial will enable us to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.